Treatment | Trial name | Enrollment | Median progression-free survival (months) | Median overall survival (months) |
Fulvestrant plus palbociclib or placebo | PALOMA-3[1,2] | 521 patients with progressive disease | 9.5 versus 4.6* | 40 versus 30* |
Fulvestrant plus ribociclib or placebo | MONALEESA-3[3] | 726 postmenopausal patients:
|
|
|
Fulvestrant plus abemaciclib or placebo | MONARCH2[4] | 669 postmenopausal patients with progressive disease | 16.4 versus 9.3* | 47 versus 37* |
HER2: human epidermal growth factor 2.
* Statistically significant.
¶ Within 12 months after completion of adjuvant or neoadjuvant endocrine therapy.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟